People are different and so is their cancer, patients should be treated individually.

IndiTreat test process

Following consultation with the doctor and/or oncologist (1), a biopsy of the patient’s primary tumor or a metastasis usually from the liver (2) is sent to 2cureX laboratories in Denmark or Germany.

2cureX generates thousands of copies called microtumors (3). Drugs and drug combinations are applied to the microtumors and their growth responses are monitored for typically up to 14 days (4). A report is sent to the oncologist detailing microtumor resistance and sensitivity to each treatment (5). Based on the report, the oncologist and doctor can make better informed treatment recommendations to the individual patient (6).

Safe transport of samples to 2cureX

We achieve the safe transport of viable biopsies through a continuous temperature-controlled chain from your clinic to our laboratories with 2cureX distribution partners. We will set up a conference call with you and your team to ensure the safe transport of the consignments.

Follow IndiTreat test results online

A comprehensive lab report will be available within approximately 14 working days after we receive the tumor sample at the 2cureX lab. The physician will be able to follow the output of the IndiTreat test through our password protected customer portal at

Contact us

Please contact 2cureX for more information

Phone: +45 22115399

Upcoming events

September 15, 2021 at 15:00 (CET)

Interview with CEO Fernando Andreu (organized by Mangold) Open participation. Details provided later.

Read more

September 23, 2021

CSO Ole Thastrup will speak at the conference “Week of Health and Innovation 2021” in Odense, Denmark

Read more and Register

September 28, 2021

Redeye Medtech & Diagnostics Investor meeting

Read more

September 29, 2021

Mangold Investor Lunch

Read more

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs